Related Experiment Videos
Are there differences between women's and men's antidepressant responses?
Frederic M Quitkin1, Jonathan W Stewart, Patrick J McGrath
1Department of Therapeutics, New York State Psychiatric Institute and Columbia university college of Physicians and Surgeons, New York 10032, USA. quitkin@pi.cpmc.columbia.edu
The American Journal of Psychiatry
|November 2, 2002
Summary
Patient sex and menopausal status generally do not impact antidepressant treatment outcomes in adults up to 65. While women showed a superior response to MAOIs, the clinical significance remains uncertain.
Area of Science:
- Psychiatry
- Clinical Pharmacology
- Neuroscience
Background:
- Antidepressant efficacy is a critical area in mental health treatment.
- Understanding patient-specific factors influencing treatment response is essential for personalized medicine.
Purpose of the Study:
- To investigate the influence of patient sex on the effectiveness of antidepressant medications.
- To explore potential differences in treatment outcomes between men and women across various antidepressant classes.
Main Methods:
- Retrospective analysis of data from 1,746 adult patients (18-65 years).
- Comparison of treatment responses to tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs), fluoxetine, and placebo.
- Examination of menopausal status effects by comparing female patients younger and older than age 50, 52, 54, and 56.
Main Results:
- Equivalent response rates to tricyclics and fluoxetine were observed in both men and women, irrespective of age (including those over 50).
- Women demonstrated a statistically significant superior response to MAOIs compared to men.
- Placebo response rates were consistent across all demographic groups analyzed.
Conclusions:
- Sex and menopausal status may not be significant factors in the antidepressant treatment of adult patients up to 65 years of age.
- The statistically superior response of women to MAOIs warrants further investigation for potential clinical relevance.
- Current findings suggest a need to re-evaluate the role of sex and menopausal status in guiding antidepressant selection for this patient population.